Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.64 |
| ▸ | EGFR | P00533 | 9/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970665 | 0.86 | MAP2K1 (0.73) | SRCEGFRERBB2MAP2K1RAF1 | |
| SCHEMBL27614725 | 0.82 | SRC (0.79) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL6187562 | 0.80 | SRC (0.64) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL6182450 | 0.80 | SRC (0.83) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL6183180 | 0.80 | SRC (0.67) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL6181489 | 0.80 | SRC (0.84) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL2978588 | 0.79 | SRC (0.84) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL6185368 | 0.79 | SRC (0.85) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL6379902 | 0.78 | SRC (0.79) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL6185084 | 0.78 | SRC (0.83) | SRCEGFRERBB2MAP2K1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767671-B2 | 3-Quinolinecarbonitrile protein kinase inhibitors | WYETH (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | WYETH (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062281-A1 | 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS | RAF1, KRAS, NRAS | SRC 240/4885EGFR 895/4885ERBB2 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.